drugset / Trial / NCT07557615

hCG Treatment for Rehabilitation From a TBI

NCT07557615

Phase 0 Not yet recruiting 50 enrolled VA Office of Research and Development
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.

Timeline

Start
2026-10-01
Primary completion
2029-07-01
Completion
2029-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ovidrel Protein / enzyme biologic 125 ug Subcutaneous